Commodore International

Hock E. Tan and John Arnold to Join Meta Board of Directors

Retrieved on: 
Wednesday, February 14, 2024
Enron, Broadcom Inc., IDT, General Motors, Arnold Ventures LLC, Silicon, Education, DoorDash, Entrepreneurship, Commodore International, Dropbox, PayPal, Lead, Executive, McKinsey & Company, ICS, AGI, Integrated Device Technology, PepsiCo, Management

MENLO PARK, Calif., Feb. 14, 2024 /PRNewswire/ -- Meta today announced that Hock E. Tan and John Arnold have been elected to the company's board of directors, effective immediately.

Key Points: 
  • MENLO PARK, Calif., Feb. 14, 2024 /PRNewswire/ -- Meta today announced that Hock E. Tan and John Arnold have been elected to the company's board of directors, effective immediately.
  • Mark Zuckerberg, Founder and CEO of Meta, said, "I'm excited to share that Hock Tan and John Arnold are joining Meta's board of directors.
  • "I am pleased to join the Meta Board and contribute to achieving the company's vision," said Tan.
  • Hock Tan has served as Broadcom's President & CEO and a member of the Board of Directors since March 2006.

Cavco Industries Announces Planned Acquisition of Manufactured and Modular Home Builder the Commodore Corporation

Retrieved on: 
Monday, July 26, 2021
Cars, Commodore International, West Chester, Pennsylvania, Commodore 64, Mid-size cars, Sedans, Station wagons, Holden Commodore, MOS Technology

Commodore is the largest independent builder of manufactured and modular housing in the United States, operating under a variety of brand names such as Commodore Homes of Pennsylvania, Commodore Homes of Indiana, Colony Homes, MidCountry Homes, Pennwest Homes and R-Anell Homes.

Key Points: 
  • Commodore is the largest independent builder of manufactured and modular housing in the United States, operating under a variety of brand names such as Commodore Homes of Pennsylvania, Commodore Homes of Indiana, Colony Homes, MidCountry Homes, Pennwest Homes and R-Anell Homes.
  • In addition to manufacturing, Commodore also participates in commercial lending operations with its dealers that Cavco will also acquire and continue the existing programs.
  • Bill Boor, Cavco President and Chief Executive Officer, said, During the acquisition process, we have developed a tremendous respect for what has been accomplished at Commodore under Barry Sheins leadership.
  • In addition to approaches Cavco can bring to the Commodore operations, Commodore has developed and implemented advanced manufacturing technologies that will lead to significant improvements to the Cavco operations.

Xilis Raises $70 Million Series A Financing to Advance Diagnostic and Drug Discovery and Development Platform Leveraging Proprietary MicroOrganoSphere™ Technology

Retrieved on: 
Thursday, July 8, 2021
Science, Stem cells, Biotechnology, Research, Pharmaceutical, Oncology, Health, Clinical trials, Commodore International, MOS Technology, MOS, Tumor microenvironment, Economy of Pennsylvania, PENNSYLVANIA, Economy of the United States

Xilis, Inc., a pioneering company using its MicroOrganoSphere (MOS) technology to guide precision therapy for cancer patients and accelerate drug discovery and development, today announced the close of a $70 million Series A financing.

Key Points: 
  • Xilis, Inc., a pioneering company using its MicroOrganoSphere (MOS) technology to guide precision therapy for cancer patients and accelerate drug discovery and development, today announced the close of a $70 million Series A financing.
  • They have developed the scalable MOS technology to analyze patients own tumors in their native microenvironment a breakthrough achievement.
  • Proceeds from the Series A funding will further advance Xilis proprietary MOS technology, expand its AI-driven capabilities, fund clinical studies for diagnostic development, and validate the use of MOS technology with biopharma partners.
  • Xilis proprietary MicroOrganoSphere (MOS) technology consists of miniature patient tumors that capture the full microenvironment and heterogeneity and provides an automated and scalable solution.

Spherix Urges Shareholders to Approve Purchase of CBM BioPharma, Inc. Assets at Special Meeting

Retrieved on: 
Monday, August 19, 2019
Companies, Dividend, Shareholders, Commodore International, Industries, Technology

The acquisition of the CBM BioPharma, Inc. ("CBM") pharmaceutical assets is an integral step in building Spherix into a cutting edge pharmaceutical company.

Key Points: 
  • The acquisition of the CBM BioPharma, Inc. ("CBM") pharmaceutical assets is an integral step in building Spherix into a cutting edge pharmaceutical company.
  • Effectuating the dividend is contingent upon obtaining the necessary votes for the CBM acquisition at the Special Meeting to be held on September 5th.
  • The dividend will be paid upon the consummation of the transaction with CBM to shareholders of record prior to the date of such consummation.
  • Should Spherix not receive the necessary votes to acquire the CBM assets on September 5th, it is unlikely that the Hoth dividend will be declared.

Altium Gathers Industry Luminaries and Designers for 3rd Annual AltiumLive Summit

Retrieved on: 
Monday, August 5, 2019
Home computers, Electronic engineering, Companies, Altium, La Jolla, San Diego, Bil Herd, Commodore 128, Commodore International, PCB, Electronics

"We designed AltiumLive, the industry's only conference dedicated exclusively to PCB design, with the sole purpose of building a community of electronics professionals.

Key Points: 
  • "We designed AltiumLive, the industry's only conference dedicated exclusively to PCB design, with the sole purpose of building a community of electronics professionals.
  • AltiumLive brings together a diverse group of industry experts and innovators covering a wide breadth of topics that expand beyond PCB design.
  • Bil Herd, MCG LLC CEO and designer of the Commodore 128 said of AltiumLive 2018, "It wasn't just about Altium.
  • The AltiumLive 2019: Annual PCB Design Summit will take place October 9-11 at the Loews Coronado Bay Resort in San Diego, California.

Spherix Reports First Quarter 2019 Results of $11,937,000 in Assets and $982,000 in Liabilities

Retrieved on: 
Thursday, May 16, 2019
Companies, Communication, Forward-looking statement, Dividend, CBM, Commodore International, Financial risk, Computer companies, Business

The 20% shareholder stake in CBM will give Spherix the ability to participate in any dividends declared by CBM in the future.

Key Points: 
  • The 20% shareholder stake in CBM will give Spherix the ability to participate in any dividends declared by CBM in the future.
  • Mr. Anthony Hayes, CEO of Spherix stated, "The revised negotiated terms with CBM BioPharma in the Asset Purchase Agreement will introduce valuable assets into the Spherix family.
  • These statements are subject to a number of risks and uncertainties regarding the businesses of Spherix and the transaction, and actual results may differ materially.
  • However, while Spherix may elect to update these forward-looking statements at some point in the future, Spherix specifically disclaims any obligation to do so.

Spherix Issues Letter to Shareholders

Retrieved on: 
Tuesday, April 2, 2019
Articles, Companies, Corporate finance, Contract law, Criminal law, Due diligence, Commodore International, CBM, Economy

With more than $13,000,000 in assets and less than 9,000,000 in outstanding shares, we are moving Spherix in the right direction.

Key Points: 
  • With more than $13,000,000 in assets and less than 9,000,000 in outstanding shares, we are moving Spherix in the right direction.
  • The CBM transaction, announced in October of last year, brings to Spherix exclusive drug development rights from world-renowned partners including Wake Forest Innovations and the University of Texas at Austin.
  • As part of our due diligence, Spherix funded a preclinical analysis of KPC34, one of the drugs exclusively licensed by CBM.
  • We will continue working with Dr. Quraishi to identify other life science assets for Spherix to acquire that would complement our existing portfolio.

Spherix Provides Video Demonstration of CBM Drug Reversing Paralysis in Preclinical Study

Retrieved on: 
Wednesday, October 17, 2018
CBM, Commodore International, PLOS One, Academic publishing, Publishing, Computing

NEW YORK, Oct. 17, 2018 /PRNewswire/ -- Spherix Incorporated (Nasdaq: SPEX) today provided shareholders with a video demonstration on its website of the potential effectiveness of CBM BioPharma, Inc.'s ("CBM) innovative drug platform.

Key Points: 
  • NEW YORK, Oct. 17, 2018 /PRNewswire/ -- Spherix Incorporated (Nasdaq: SPEX) today provided shareholders with a video demonstration on its website of the potential effectiveness of CBM BioPharma, Inc.'s ("CBM) innovative drug platform.
  • The notable video , which was recorded at Wake Forest University, visually demonstrates the potential effectiveness of one of CBM's primary drug candidates known as KPC34.
  • Anthony Hayes, CEO of Spherix, stated, "This remarkable video demonstrates the tremendous potential for this drug to treat ALL.
  • The video was part of a written submission on KPC34 to PLOS OneTM a peer reviewed medical journal.